EU Authorised Representative for Medical Devices and IVDs Across Europe
For manufacturers based outside the European Union, bringing medical devices or in vitro diagnostic devices into the European market involves more than product quality, technical documentation and regulatory preparation. Before a device can be placed on the European market, the manufacturer must appoint an EU Authorized Representative who is physically located in the European Union and legally recognised as the manufacturer’s official representative. This role is essential under the Medical Device Regulation and the In Vitro Diagnostic Medical Device Regulation because regulators need a responsible local party who can communicate, provide documentation and support compliance activities when required. An eu-authorized-representative is not simply a name on a label. They serve as the legal presence of a non-EU manufacturer and play a vital role in ensuring market access, regulatory trust and ongoing post-market accountability.
Why an EU Authorized Representative Is Required
European medical device rules are designed to protect patients, healthcare professionals and users by ensuring that every product placed on the market has a clear chain of responsibility. If a manufacturer operates outside the European Union, regulators cannot always interact with them as easily as they would with a locally established company. This is where the EU Authorized Representative becomes necessary. The representative provides a formal local presence and serves as the official point of communication for Competent Authorities, Notified Bodies and other regulatory stakeholders.
Without appointing an authorised representative, a non-EU manufacturer cannot legally place medical devices or IVDs on the European market. This requirement applies across a broad spectrum of products, from low-risk devices to advanced diagnostic technologies. The requirement exists before market entry, which means the representative must be appointed early in the compliance process rather than treated as a final administrative step. For manufacturers planning European distribution, choosing the right EU Authorized Representative for Medical Devices and IVDs can directly affect registration readiness, documentation control and long-term regulatory stability.
The Written Mandate Between Manufacturer and Representative
The connection between the manufacturer and the EU Authorized Representative must be formalised through a written mandate. This mandate defines the tasks the representative is authorised to perform and confirms the obligations both parties must follow. It is a critical compliance record as it defines the scope of representation, responsibilities, communication roles and the actions required if compliance issues occur.
An unclear or weakly drafted mandate can cause uncertainty at critical moments, particularly during authority requests, inspections, complaint handling or corrective actions. A strong mandate should clearly describe how documents will be made available, how regulatory communication will be handled, how incident information will be shared and what happens if the manufacturer does not meet its duties. For this reason, the mandate should be prepared carefully and reviewed before device registration or market placement begins.
Label and Packaging Requirements
The name and address of the EU Authorized Representative must appear on the device label, packaging or related product information as required by the applicable regulation. This allows authorities, distributors, healthcare professionals and users to identify the local representative linked to the device. It also reinforces the representative’s role as the official European presence for a manufacturer located outside the European Union.
Accurate labelling is essential because incorrect or missing representative details can lead to compliance issues and possible delays in market access. Manufacturers must ensure that artwork, instructions, declarations and registration data are consistent before product release. If the representative changes, labelling and registration details may also need to be updated in a controlled and timely manner.
Documentation Review and Availability
A key responsibility of an EU Authorized Representative for Medical Devices and IVDs is to ensure that essential compliance documents are available and correctly prepared. This includes checking that the EU Declaration of Conformity exists, that technical documentation has been compiled and that the manufacturer has followed an appropriate conformity assessment route for the device type and risk class.
The representative may also be required to retain or access copies of technical files, declarations and Notified Body certificates. These documents must be available for inspection by Competent Authorities for the required retention period after the last device has been placed on the market. This makes document control a central part of the relationship between manufacturer and representative. Manufacturers should maintain updated records and ensure that the representative can respond quickly if regulators request information.
Communication With Competent Authorities and Notified Bodies
The EU Authorized Representative acts as the official communication channel between the non-EU manufacturer and European regulatory authorities. If a Competent Authority requests information, samples, technical documentation or clarification, the representative is expected to support the response process. The representative may also communicate with Notified Bodies when required, especially where certificates, conformity assessment or corrective actions are involved.
This communication function goes beyond simply passing messages. A dependable representative should understand regulatory requirements, maintain accurate records and ensure responses are delivered within required timelines. Delayed or incomplete responses can create serious issues for manufacturers, including market restrictions or further regulatory review. Therefore, manufacturers should partner with a representative who has strong regulatory expertise and well-defined internal systems.
Post-Market Surveillance and Incident Support
Medical device compliance does not end after market entry. After a device is in circulation, manufacturers must continuously monitor performance, complaints, incidents and safety indicators. The EU Authorized Representative has a role in supporting this post-market responsibility by passing complaints and incident information to the manufacturer without delay.
This is particularly critical when information originates from clinicians, patients, users, distributors or authorities. Timely communication helps the manufacturer assess whether further investigation, reporting, field safety action or corrective action is needed. A strong representative understands that post-market surveillance is not just paperwork. It is part of patient safety, product improvement and ongoing regulatory trust.
Registration Responsibilities and EUDAMED
Under European regulatory systems, manufacturer and representative details must be registered as required. The EU Authorized Representative may support the registration of both the manufacturer and representative information in EUDAMED. Accurate registration helps authorities identify responsible parties, review device information and maintain market oversight.
Manufacturers should prepare complete company details, device information, certificates and declarations before registration activities begin. Any inconsistency between labels, declarations, technical files and registration records can create delays or compliance questions. The representative’s involvement helps ensure that required information is properly aligned and available when needed.
When the Representative Must Take Action
An EU Authorized Representative also carries responsibilities if the manufacturer does not fulfil regulatory requirements. If significant non-compliance arises and is not corrected by the manufacturer, the representative may need to terminate the mandate and notify relevant authorities and the Notified Body where relevant. This responsibility shows why the role is more than administrative.
The representative holds legal responsibility and cannot overlook serious compliance breaches. Manufacturers should therefore treat the representative as a regulatory partner rather than a passive service provider. Clear communication, regular document updates and defined responsibilities help avoid misunderstandings and minimise risk throughout the product lifecycle.
Choosing the Right EU Authorized Representative
Choosing an EU Authorized Representative eu-authorized-representative requires careful consideration. Manufacturers should look for regulatory competence, experience with medical devices and IVDs, document handling capability, clear response procedures and a strong understanding of European requirements. The representative should effectively handle authority communication, maintain records and guide the manufacturer on practical compliance matters.
Cost alone should not determine the choice. An ineffective representative may lead to delays, communication gaps and increased risk, whereas a strong representative can support confidence during market entry and beyond. The correct selection provides non-EU manufacturers with a reliable European presence and enables smoother regulatory management.
Conclusion
An EU Authorized Representative is a mandatory requirement for non-EU manufacturers aiming to introduce medical devices or IVDs into the European market. The role covers legal representation, document availability, regulatory communication, complaint management, registration assistance and intervention in cases of serious non-compliance. Under the Medical Device Regulation and In Vitro Diagnostic Medical Device Regulation, appointing an authorised representative is not optional and should be completed before market placement begins. By choosing a competent EU Authorized Representative for Medical Devices and IVDs, manufacturers can strengthen compliance, support patient safety and build a reliable foundation for long-term access to the European market.